BD's PharMingen buy to help "speed" conversion of research products to clinical use, firm tells analysts.
This article was originally published in The Gray Sheet
BD/PHARMINGEN COMBINATION TO ACCELERATE CONVERSION OF RESEARCH use reagents to clinical products by capitalizing on Becton Dickinson's expertise in developing products for clinical use and PharMingen's experience in the research market, Deborah Neff, president of BD Immunocytometry Systems, told analysts April 24 in New York City.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.